Scientists harness Patients' own immune cells to attack Treatment-Resistant melanoma

NCT ID NCT07651618

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a therapy called Perkileucel, made from a patient's own immune cells (tumor-infiltrating lymphocytes). These cells are collected from a surgically removed melanoma tumor, grown in a lab, and then infused back into the patient. Before the infusion, patients receive a short course of chemotherapy to prepare their body. The goal is to see if this personalized cell therapy can shrink or control melanoma that has not responded to immune checkpoint inhibitors. The trial involves 10 adults with advanced melanoma and includes close monitoring for safety and effectiveness over several years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Perkileucel (tumor-infiltrating lymphocytes)

What this could lead to

If it works, this could offer a new treatment option for people with advanced melanoma that has stopped responding to other therapies.

What could go wrong

This is a small, early-phase trial, so results may not apply to everyone. The treatment involves intensive chemotherapy and carries risks like infection and organ damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Royal Perth Hospital

    Perth, Western Australia, 6000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact